Reports

German physicians not pressured to switch to biosimilar infliximab

Home/Reports | Posted 02/10/2015

Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.

Pivotal clinical trials for bevacizumab biosimilars

Home/Reports | Posted 18/09/2015

Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.

Generics use in Italy could save Euros 1.4 billion per year

Home/Reports | Posted 05/06/2015

A report published by Italian generics association Assogenericion on 5 May 2015 points to the fact that generics are crucial in the containment of pharmaceutical expenditure in Italy.

Clinical programmes for oncology biosimilars

Home/Reports | Posted 28/08/2015

Biosimilars for oncology drugs are currently under development. These include biosimilars of blockbusters such as Roche’s Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab).

Doctors’ survey reveals lack of confidence in biosimilars

Home/Reports | Posted 21/08/2015

Online physician’s platform and community QuantiaMD survey of 300 primary care physicians and specialists in the US has found a lack of confidence concerning biosimilars. 

Clinical programmes for anti-TNF biosimilars

Home/Reports | Posted 14/08/2015

Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade (infliximab).

Cost reductions due to biosimilars in Europe

Home/Reports | Posted 07/08/2015

Biosimilars have been approved in the European Union since 2006 in the classes of erythropoietin (EPO), human growth hormone (HGH), granulocyte colony-stimulating factor (G-CSF) and anti-tumour necrosis factor (anti-TNF).  Despite the fact that they have been in use since 2006, the prices for EPO, HGH and G-CSF classes of drugs in some countries have not reduced by as much as some might have expected. There is also a significant variation between different countries in Europe [1].

Biosimilars penetration in Europe varies widely

Home/Reports | Posted 31/07/2015

The penetration of biosimilars in Europe varies widely between countries and therapy areas [1].

Generics prices in US decrease again in 2013

Home/Reports | Posted 03/07/2015

In 2013, retail prices for 280 widely used generics fell by an average of 4.0%, compared to the US inflation rate, which was 1.5% over the same period.

UK patient groups say pharma needs to reduce cost of medicines

Home/Reports | Posted 19/06/2015

A report produced by patient research organization PatientView has found that UK patient groups think that the pharma industry could be doing a lot more for patients.